Table 1

Comparison of clinical data between patients with SLE with high or low 2019 criteria score (n=120)

Clinical characteristicsMean±SD/Positive (%)Nominal p value
High 2019 criteria score (n=59)Low 2019 criteria score (n=61)
Age35.83±12.6634.93±13.380.705
Sex, male/female14/456/550.051
Disease duration, months1.0 (0.5, 6.0)1.0 (0.5, 3.0)0.141
SLEDAI21.12±4.8016.34±4.610.0001
2019 criteria score30.40±3.9219.95±10.270.0001
Class II or V lupus nephritis9 (5.25%)24 (39.34%)0.003
Class III or IV lupus nephritis50 (84.75%)37 (60.66%)
Fever18 (30.51%)9 (14.75%)0.039
Mucocutaneous domain
 Acute cutaneous lupus27 (45.76%)5 (8.20%)0.003
 Subacute cutaneous lupus or discoid rash2 (3.39%)00.240
 Non-scarring alopecia10 (16.95%)3 (4.92%)0.042
 Oral ulcer4 (6.78%)00.055
Musculoskeletal domain17 (35.59%)4 (6.56%)0.002
Serosal domain27 (45.76%)7 (11.48%)<0.0001
Neuropsychiatric domain2 (3.39%)1 (1.64%)0.616
Haematological domain
 Leucopoenia35 (59.32%)19 (31.15%)0.002
 Thrombocytopenia21 (35.59%)5 (8.20%)0.002
 Autoimmune haemolysis7 (11.86%)1 (1.64%)0.031
Laboratory criteria
 Anti-β2GP1 antibodies or lupus anticoagulant*17 (28.81%)15 (24.59%)0.601
Low complement
 C358 (98.31%)47 (77.05%)0.0005
 C453 (89.83%)41 (67.21%)0.0026
Anti-dsDNA antibody48 (81.36%)20 (32.79%)<0.0001
Anti-Sm antibody24 (40.68%)16 (26.23%)0.0932
  • P-values <0.05 were considered as significance and marked in bold.

  • *The data of lupus anticoagulant were absent.

  • SLEDAI, SLE disease activity index.